Production (Stage)
Sensei Biotherapeutics, Inc.
SNSE
$0.295
-$0.014-4.53%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -6.92% | -43.08% | -18.70% | -40.61% | -34.30% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -16.68% | -20.61% | 1.11% | -23.48% | -20.69% |
| Operating Income | 16.68% | 20.61% | -1.11% | 23.48% | 20.69% |
| Income Before Tax | 14.11% | -4.80% | -1.81% | 23.91% | 21.47% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 14.11% | -4.80% | -1.81% | 23.91% | 21.47% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 14.11% | -4.80% | -1.81% | 23.91% | 21.47% |
| EBIT | 16.68% | 20.61% | -1.11% | 23.48% | 20.69% |
| EBITDA | 13.80% | 21.48% | -1.16% | 24.24% | 21.14% |
| EPS Basic | 14.60% | -4.01% | -3.30% | 7.54% | 3.22% |
| Normalized Basic EPS | 12.41% | 17.26% | -3.38% | 5.63% | 4.21% |
| EPS Diluted | 14.60% | -4.01% | -3.30% | 7.54% | 3.22% |
| Normalized Diluted EPS | 12.41% | 17.26% | -3.38% | 5.63% | 4.21% |
| Average Basic Shares Outstanding | 0.57% | 0.74% | -1.43% | -17.71% | -18.85% |
| Average Diluted Shares Outstanding | 0.57% | 0.74% | -1.43% | -17.71% | -18.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |